伴随诊断相关抗肿瘤药物的发展现状

张俊琦; 周斌<sup>*</sup>

引用本文:	张俊琦,周斌.伴随诊断相关抗肿瘤药物的发展现状[J].中国现代应用药学,2018,35(3):454-459.
	Zhang Junqi,Zhou Bin.Progresses of Companion Diagnostics Relatede Antitumor Drugs[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(3):454-459.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2195次下载 2296次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
伴随诊断相关抗肿瘤药物的发展现状
张俊琦¹, 周斌²
1.复旦大学附属儿科医院药剂科, 上海 201102;2.同济大学附属东方医院血管外科, 上海 200120

摘要:

肿瘤基础研究和基因分子生物学技术的进步促进了伴随诊断和相关抗肿瘤药物的发展。目前伴随诊断应用的最大分支是通过伴随诊断获得患者针对特定治疗药物的治疗反应的信息，协助制定治疗方案，实现患者的个体化治疗。但伴随诊断及其相关药物在研发和应用上与传统药物有较大不同，本文试对其做一综述。

关键词: 伴随诊断抗肿瘤药物发展现状

DOI：10.13748/j.cnki.issn1007-7693.2018.03.034

分类号:R979.1

基金项目:

Progresses of Companion Diagnostics Relatede Antitumor Drugs

Zhang Junqi¹, Zhou Bin²

1.Pharmacy Department, Children's Hospital, Fudan University, Shanghai 201102, China;2.Vascular Surgery Department, East Hospital, Tongji University School of Medicine, Shanghai 200120, China

Abstract:

Companion diagnostics (CDx) and CDx related antitumor drugs develope very fast recently for the improvement of basic research of oncomolecular biology. Antitumor drugs is the largest branch of CDx nowadays. Doctors may prognosis drug effect by CDx, which is important in making treatment plan and individualized treatment. There are many differences between traditional chemotherapy drugs and CDx related drugs. Here is a review of companion diagnostics related antitumor drugs.

Key words: companion diagnostics antitumor drugs progress